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One of themost striking examples of dysfunctional hypothalamic signaling of energy home-
ostasis is observed in patients with hypothalamic lesions leading to hypothalamic obesity
(HO). This drastic condition is frequently seen in patients with craniopharyngioma (CP), an
embryological tumor located in the hypothalamic and/or pituitary region, frequently causing
not only hypopituitarism, but also leading to damage of medial hypothalamic nuclei due
to the tumor and its treatment. HO syndrome in CP patients is characterized by fatigue,
decreased physical activity, uncontrolled appetite, and morbid obesity, and is associated
with insulin and leptin resistance. Mechanisms leading to the profoundly disturbed energy
homeostasis are complex. This review summarizes different aspects of important clinical
studies aswell as data obtained in rodent studies. In addition amodel is provided describing
howmedial hypothalamic lesion can interact simultaneously with several weight-regulating
circuitries.
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HYPOTHALAMIC OBESITY IN PATIENTS WITH
CRANIOPHARYNGIOMA: SUMMARY OF KEY CLINICAL
FINDINGS
Excessive weight gain is one of the most distressing manifesta-
tions of hypothalamic injury associated with CP. In 30% of all
patients with hypothalamic tumors, BMI is increased at the time
of diagnosis (Muller et al., 2004). After surgery, hyperphagia and
obesity occur on average in about 50% of all CP patients (Cur-
tis et al., 1994; Muller et al., 2001; Muller, 2006), although study
results vary from 6% (Galatzer et al., 1981) to 91% (Imura et al.,
1987; Muller et al., 2004), with higher rates in patients with hypo-
thalamic damage. In children and adolescents, the incidence of
severe obesity following CP resection surgery is between 22 and
62% (Brauner et al., 1987; Sorva, 1988; Muller, 2008). Struc-
tural defects in parts of the medial hypothalamus due to surgery,
irradiation, or the tumor itself often cause treatment resistant
uncontrolled appetite and rapid weight gain. Tumor resection
with and without radiotherapy represents the therapeutic stan-
dard of care. But following treatment, patients often suffer from
partial hypopituitarism or panhypopituitarism. Despite optimal
endocrine management, uncontrolled appetite and rapid weight
gain are common, typically most pronounced during the ﬁrst
months after surgery (Sorva, 1988; Muller et al., 2004), making
severe obesity a major risk factor for CP related morbidity. Risk
factors for developing obesity in CP patients include large hypo-
thalamic lesions affecting several medial hypothalamic nuclei such
as the arcuate nucleus (ARC), ventromedial nucleus (VMN), and
the dorsomedial nucleus (DMN), and tumors that reach the ﬂoor
of the third ventricle; hydrocephalus; transcranial surgery, which
often causes greater damage to the hypothalamus compared to
transnasal surgical tumor removal; aggressiveness of resection;
reoperation for tumor recurrence; and hypothalamic irradiation
(Muller et al., 2007; Gardner et al., 2008;Vinchon et al., 2009; Roth
et al., 2011c; Figure 1).
KEY BRAIN AREAS AND NEURONAL PATHWAYS INVOLVED
IN ENERGY HOMEOSTASIS
HYPOTHALAMIC NUCLEI ANDWEIGHT REGULATORY PATHWAYS
The hypothalamus is central to regulation of energy homeosta-
sis. Hypothalamic nuclei are the target of circulating peptides,
including leptin, insulin, peptide YY3–36 (PYY), and ghrelin, as
well as nutrients such as free fatty acids, glucose, and amino acids
(Schwartz et al., 2000; Cota et al., 2006; Morton et al., 2006; Par-
ton et al., 2007). Changes in the circulating level of these afferent
inputs can trigger potent efferent responses affecting both food
intake (FI) and energy expenditure (EE) in the regulation of energy
homeostasis. It is well established that insulin and leptin are two
peripherally secreted hormones that play critical roles in FI and
EE (Schwartz et al., 2000) and that levels of both are proportionate
to body fat and interact with their respective receptors expressed
in the ARC, a key brain area transmitting peripheral weight-
regulating signals to the brain. Many neurons are regulated by
leptin and insulin, and central administration of either hormone
reduces FI and body weight. The main mediators in the hypothal-
amic regulation of energy intake and EE appear to be proopiome-
lanocortin (POMC) and neuropeptide-Y/agouti-related peptide
(NPY/AgRP) producing neurons, which are concentrated in the
ARC and project mainly to the paraventricular nucleus (PVN)
in the hypothalamus but also to the VMN, lateral hypothalamus
(LHA), aswell as theDMNand themedian preoptic area (Bai et al.,
1985; Kerkerian and Pelletier, 1986; Schwartz et al., 2000; Schwartz
and Gelling, 2002). Alpha-melanocyte stimulating hormone (α-
MSH), a posttranslational product of the prohormone POMC, is
one of the key weight-regulating neuropeptides (Bai et al., 1985;
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FIGURE 1 | Representative coronal (A), midsagittal brain MRI (B), and
schematic overview (C,D) of a patient with hypothalamic obesity and
hyperphagia following surgery for CP. Lesion affects the ARC, VMN,
DMN, and the posterior part of the AHA, but not the LHA. DMN,
dorsomedial nucleus; LHA, lateral hypothalamus; VMN, ventromedial
nucleus; PVN, paraventricular nucleus; ARC, arcuate nucleus; AHA, anterior
hypothalamic area.
Kerkerian and Pelletier, 1986; Schwartz et al., 2000; Schwartz and
Gelling, 2002). The VMN contains gamma-amino butyric acid-
(GABA)ergic and anorexigenic brain-derived neurotrophic factor
(BDNF) neurons and is an important nucleus for insulin depen-
dent neurotransmission and is an important site for the regulation
of the autonomous nervous system outﬂow from the brain (Mor-
ton et al., 2006;Berthoud andMorrison,2008). TheDMNcontains
GABAergic neurons but also expresses NPY in particular in its
compact region and expresses leptin receptors such as the ARC,
VMN, and PVN (Choi et al., 1999; Glavas et al., 2007). NPY in
the DMN may play a role in maintaining energy homeostasis (Bi,
2007). The PVN receives projections from NPY-synthesizing neu-
rons located in the ARC, which are also present in the brainstem
(Sawchenko et al., 1985; Sahu et al., 1988). Neurons that synthe-
size the hunger hormones, MCH or orexin A, are located in the
LHA and are downstreammediators of feeding responses initiated
by ARC neurons (Schwartz, 2006). The PVN contains a variety
of appetite suppressing peptides, such as corticotropin-releasing
factor (CRF), thyrotropin-releasing hormone (TRH), and oxy-
tocin, that promote negative energy balance by conveying input
from the ARC to other key brain areas such as the NTS (Schwartz,
2006; Blevins et al., 2009). Recent evidence also suggests that the
adiposity hormones act in brain areas linked with food reward,
whichmediatemotivation and the decision to eat. (Petrovich et al.,
2002; Figlewicz and Benoit, 2009). Limbic and reward circuitry are
densely innervated by neurocircuits originating in the hypothal-
amus and are directly responsive to ghrelin, leptin, and insulin
(Figlewicz, 2003; Figlewicz et al., 2007). These structures receive
signiﬁcant cortical input aswell, sending projections to the nucleus
accumbens and pallidum, and from there, via the LHA, to motor
regions charged with executing feeding behavior.
HINDBRAIN SIGNALING AND PERIPHERAL REGULATORS
Peptide YY3–36, glucagon-like peptide (GLP)-1, pancreatic
polypeptide (PP), and cholecystokinin (CCK) are gastrointestinal-
derivedhormones that are releasedpostprandially inproportion to
the amount of calories ingested (Wynne et al., 2005). These anorex-
igenic hormones inhibit FI through neurons in the ARC, which
is frequently damaged in CP patients, and/or neurons located in
the hindbrain solitary tract nucleus, which is usually intact in CP
patients (Batterham et al., 2002; Small et al., 2005). Addition-
ally, plasma concentrations of orexigenic ghrelin decrease after
FI. An intact vagal-brainstem-hypothalamic pathway is required
in order for some of these hormones to exert their effects on FI
which is controversial for PYY (Batterham et al., 2002; Small et al.,
2005). Although there is published evidence that increased insulin
secretion is caused by an increased vagal tone secondary to VMN
lesions in humans (Lustig et al., 2003; Ahmet et al., 2006) as in
rats (Bray and Nishizawa, 1978), it is unclear how the increased
vagal tone and decreased sympathetic tone affect secretion of dif-
ferent gut peptides. It has been shown that the anorexigenic effects
of peripheral administration of both PYY on FI and activation
of ARC neurons are abolished following either bilateral sub-
diaphragmatic total truncal vagotomy or brainstem-hypothalamic
pathway transectioning in rodents (Abbott et al., 2005). In addi-
tion, it has been reported that disturbed adrenergic sympathetic
dysregulation in obesity inﬂuences anorexigenic gut hormone
secretion, in particular PYY release (Lin et al., 2003). Even though
vagotomy is currently a therapeutic approach for treating hypo-
thalamic obesity (HO) in CP patients (Lustig et al., 2009), from
a mechanistic standpoint it remains unclear if potential beneﬁts,
e.g., reduction of hyperinsulinemia, outweigh potential problems,
e.g., disturbed post-meal gut hormone release. Long acting GLP-
1 agonists, and orally active inhibitors of the incretin-degrading
enzyme dipeptidyl peptidase-IV are approved for treating type-2
diabetes (Bailey, 2005; DeFronzo et al., 2005), and it is compelling
to test in future studies the responsiveness to peripherally injected
gut peptides in HO, as these might offer human obesity treatment
opportunities.
HYPOTHALAMIC OBESITY: WHAT CAN BE LEARNED FROM
ELECTROLYTIC AND CHEMICAL LESION MODELS IN RODENTS?
Patients with CP often complain about uncontrolled hunger. As
early as, Brobeck et al. (1943) described rats with lesions in the
VMN as “voracious,” whereas lesions of the LHA led to anorexia
and cachexia. Electrolytic or surgical lesions in the PVN pro-
duced extreme overeating and obesity, suggesting an important
role for this nucleus in energy regulation. However, conﬂicting
results have been published. PVN lesions lead to marked stimu-
lation of FI, but variable frequencies of obesity (Tokunaga et al.,
1991, 1993). VMN-lesioned rats showed lower activity levels and
disturbed circadian rhythms, whereas rats with PVN lesions did
not (Tokunaga et al., 1991). Rats treated at neonatal age with
monosodium l-glutamate (MSG) develop neuroendocrine and
metabolic abnormalities, resulting in a phenotype of adiposity
characterized by GH deﬁciency (Kubota et al., 1994), hyperinsu-
linemia (de Souza et al., 2003), and hyperleptinemia, due to leptin
resistance (Perello et al., 2004). Vagotomy decreased high insulin
secretion induced inMSG-obese rats (Balbo et al., 2002). Neonatal
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administration of MSG to rodents and monkeys destroyed 80–
90% of the ARC, showing cell rariﬁcation and cell death most
signiﬁcantly in the rostromedial ARC, but also in the adjacent
VMNwhere cell density was not distinctly reduced (Schoelch et al.,
2002), resulting in several neuroendocrine and metabolic abnor-
malities and decreased thermogenesis. In hamster studies, MSG
decreased numbers of hypothalamic neuropeptide-Y (NPY)- and
agouti-related peptide (AgRP) ﬁbers in the PVN, because the ARC
has projections to the PVN, including α-MSH projections (Leit-
ner and Bartness, 2008). MSG-treated animals develop an obesity
syndrome in the absence of hyperphagia (Dawson et al., 1989;
Elfers et al., 2011; Roth et al., 2011b), characterized by excess fat
deposition and reduced lean body mass, accompanied by reduced
metabolic rates, due to decreased sympathetic activation of brown
adipose tissue (Poon and Cameron, 1978). Recently we developed
a rat model of combined medial hypothalamic lesion (CMHL)
affecting the VMN, DMN, and the ARC. Only the CMHL model
exhibited all key features observed in patients with HO induced by
CP (Elfers et al., 2011; Roth et al., 2011b). These features included
excessive weight gain due to increased adiposity, increased FI,
and pronounced hyperinsulinemia and hyperleptinemia. Simi-
lar to ﬁndings in CP patients (Roth et al., 2010), CMHL animals
exhibited reduced plasma levels of alpha-melanocyte stimulating
hormone and reduced ambulatory activity compared to weight-
matched controls. Ablation of the ARC/VMN can destroy the
leptin sensitive melanocortin ARC–PVN circuit affecting satiety
signaling not only in the hypothalamus but also in the hindbrain
(see model Figure 2). The CMHLmodel best mimics the complex
metabolic abnormalities observed in obese CP patients compared
to lesions to other hypothalamic areas and provides a foundation
for future pharmacological approaches to treat obesity in children
with hypothalamic damage.
HYPOTHALAMIC OBESITY: RESULTS FROM STUDIES IN
HUMANS
IMAGING STUDIES AND FOOD REWARD
Risk factors for developing obesity in CP patients include: large
hypothalamic lesions and tumors that reach the ﬂoor of the third
ventricle; hydrocephalus; aggressive resection; and hypothalamic
irradiation (Muller et al., 2007; Gardner et al., 2008;Vinchon et al.,
2009). Extensive hypothalamic inﬁltration and a completely deﬁ-
cient third ventricle have been associated with the highest risk of
obesity (DeVile et al., 1996; Pascual et al., 2008). however, results
are not entirely consistent (Daousi et al., 2005). Disturbance of the
hypothalamus by the tumor itself (Vinchon et al., 2009) and/or its
radiation/surgical treatment has been discussed as a major cause
of hyperphagia and obesity. In our own clinical series we found
in patients with morbid obesity lesions affecting several medial
hypothalamic nuclei such as ARC, VMN, and DMN (representa-
tive picture is shown in Figure 1). Functional magnetic resonance
imaging (fMRI) is a powerful tool for observing the human brain’s
in vivo responses to stimuli. The question is whether damage to
homeostatic centers, such as medial hypothalamic nuclei by CP,
also alters eating behavior by alteration of neuronal activity in
food reward brain areas (see for schematic overview Figure 2)
and whether central processing of satiety is affected. In a pilot
FIGURE 2 | Key regulators of energy homeostasis in the brain. Model
of weight regulatory circuits and hypothalamic nuclei potentially affected
by craniopharyngioma and surgery (gray area). The lesion of medial
hypothalamic nuclei (ARC, VMN, DMN) typically does not involve the
lateral hypothalamus (LHA) potentially leading to unbalanced expression
and secretion of orexigens (MCH, orexigens A and B) by the LHA.
Additionally the communication to (1) higher cortical brain areas and limbic
system involved in food reward and eating behavior, (2) pituitary, and (3)
hindbrain nuclei (AP, area postrema, NTS: solitary tract nucleus) affecting
the autonomous nervous control of effectors in pancreas, liver, adipose
tissue, GI tract, muscle, CV system might be affected as well. CRF,
corticotrophin relasing factor; TRH, thyrotropin-releasing hormone; NPY,
neuropeptide-Y; GABA, gamma aminobutyric acid; BDNF, brain-derived
neurotrophic factor; POMC, proopiomelanocortin; AgRP, agouti-related
peptide; CART, cocaine amphetamine regulated transcript; α-MSH,
alpha-melanocyte stimulating hormone.
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study, we utilized fMRI to examine food-related activity in brain
centers that control appetite. We hypothesized that hypothalamic
damage due to CP and its treatment results in enhanced percep-
tion of food reward. Participants viewed blocked photographs of
food and mean z-scores for regions of interest (ROI; bilateral N.
accumbens, insula, striatum,andmedial orbitofrontal cortex)were
calculated for the contrast of fattening> non-fattening food. Sub-
jects underwent the ﬁrst fMRI scan, received a high-calorie test
meal to suppress appetite, and had a second fMRI scan 30min
after the test meal. Before and after the scans, hunger ratings were
performed. Following the test meal, controls showed suppression
of activation in ROIs while CP patients showed trends toward
higher activation in ROIs (Roth et al., 2011a). These preliminary
data support our hypothesis that perception of food cues may be
altered in HO, especially after eating. The fMRI approach may be
applicable for performing futuremechanistic studies of the brains’
response to food in patients with HO.
CENTRAL AND PERIPHERAL PEPTIDES INVOLVED IN ENERGY
HOMEOSTASIS
There is good evidence for alterations in peripheral hormone sig-
naling in CP. Previous clinical studies showed that hypothalamic
tumor involvement leads to greater leptin resistance in patients
with CP than in obese controls (Roth et al., 1998). CP patients are
reported to be less physically active than controls with compara-
ble BMIs (Harz et al., 2003) and catecholamine levels are lower in
CP patients, indicating low sympathetic tone (Roth et al., 2007).
Plasma α-MSH levels were signiﬁcantly reduced in CP, similar to
ﬁndings in our CMHL ratmodel, whichmight explain lower EE in
peripheral tissues via reduced fat and muscle fatty acid oxidation
(Roth et al., 2010). In an ancillary study to theGermanmulticenter
study Kraniopharyngeom 2000, plasma insulin, and gut hormone
responses, such as ghrelin and PYY, in response to meal tests were
assessed in lean and obese CP patients and BMImatched controls.
Obese CP subjects had signiﬁcantly higher baseline and post-meal
insulin and weaker post-meal changes for PYY compared to obese
controls. Patients with hypothalamic CP had signiﬁcantly weaker
post-meal reduction of ghrelin levels than CP without hypothala-
mic localization (Roth et al., 2011c). In sum, prior studies of HO
have shown impaired function of peripherally released hormones
that act centrally to modulate responses to food (see Figure 3).
SUMMARY AND ETIOLOGICAL THEORIES
Damage of medial hypothalamic nuclei due to the tumor and
its treatment is frequently seen in patients with CP leading to
HO characterized by fatigue, decreased physical activity, uncon-
trolled appetite, andmorbid obesity, and is associated with insulin
and leptin resistance. Disruption of feeding circuits by damage of
medial hypothalamic nuclei has the potential to increase hunger,
by (i) enhancing the response to orexigenic signals such as ghrelin
and by stimulating the orexigenic signaling throughNPY/AgRP or
(ii) blocking the response to adiposity signals such as leptin and
inhibiting the anorexigenic POMC signaling in the hypothalamus
(Figure 2). In either case, the result can involve unopposed activa-
tion of the LHA which increases FI while decreasing sympathetic
nervous system (SNS)-mediated stimulation of EE. VMN damage
can lead to disinhibition of the vagal tone, resulting in excess
FIGURE 3 | Hypothetical model of disturbed energy homeostasis in
hypothalamic obesity.
FIGURE 4 | Summary of metabolic and clinical findings involved in
dysregulated energy balance in hypothalamic obesity.
stimulation of pancreatic β-cells, hyperinsulinemia, and obesity
(Lustig et al., 2003). Alternatively, the sympathetic nervous out-
put might be reduced, leading to decreased physical activity (Harz
et al., 2003; Roth et al., 2007). As the hypothalamic damage in
CP frequently includes the ARC, which is the main hypothalamic
binding site for hormones from the periphery (Figures 2 and 3),
the hypothalamusmight be unable to respond normally to adipos-
ity and satiety signals such as insulin, leptin, and gut hormones,
including PYY and ghrelin (Stellar, 1954; Blundell, 1982, 1990;
Inge et al., 2007). In addition, excessive weight gain could be the
result of deﬁcient hypothalamic neural circuits communicating
with corticolimbic and other brain regions to regulate appetite
and thus leading to unbalanced eating (see summary Figure 4).
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